Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Neoplasms 11Breast Neoplasms 10Head and Neck Neoplasms 5Lung Neoplasms 3Carcinoma, Squamous Cell 3Adenocarcinoma 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thoracic Neoplasms 1Squamous Non-small Cell Lung Cancer 1Squamous Cell Cancers of the Head and Neck 1Rhabdomyosarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Neuroectodermal Tumors 1Neoplasms by Site 1Lung Diseases 1

Interventions

Cetuximab 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Squamous Cell Cancers of the Head and Neck × Afatinib × Clear all
NCT02979977 2026-02-04

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Yale University

Phase 2 Completed
50 enrolled 14 charts
Head & Neck

Squamous Cell Cancers of the Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡